1.17
price up icon0.00%   0.00
after-market Handel nachbörslich: 1.22 0.05 +4.27%
loading

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

pulisher
03:33 AM

Performance Recap: Can Fate Therapeutics Inc ride the EV waveProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

03:33 AM
pulisher
Mar 11, 2026

Valuation Update: Can Fate Therapeutics Inc lead its sector in growthWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn

Mar 11, 2026
pulisher
Mar 09, 2026

Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

FATE: FT819 shows promising efficacy and safety in lupus nephritis, with pivotal trials set for later this year - TradingView

Mar 09, 2026
pulisher
Mar 08, 2026

Dividend Watch: Can Fate Therapeutics Inc. ride the EV waveCEO Change & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 08, 2026
pulisher
Mar 07, 2026

CEO Change: Can Fate Therapeutics Inc keep up with sector leaders2026 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo

Mar 07, 2026
pulisher
Mar 07, 2026

Risk Analysis: Can Fate Therapeutics Inc lead its sector in growthJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Fed Meeting: Can Fate Therapeutics Inc beat the S P 5002025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 05, 2026

Bull Bear: Can Fate Therapeutics Inc lead its sector in growthFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Mar 05, 2026
pulisher
Mar 05, 2026

The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant

Mar 05, 2026
pulisher
Mar 04, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 04, 2026
pulisher
Mar 03, 2026

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire

Mar 03, 2026
pulisher
Mar 03, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga

Mar 03, 2026
pulisher
Mar 03, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm

Mar 03, 2026
pulisher
Mar 03, 2026

FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 01, 2026

Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn

Mar 01, 2026
pulisher
Feb 28, 2026

Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail

Feb 28, 2026
pulisher
Feb 27, 2026

Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView

Feb 27, 2026
pulisher
Feb 26, 2026

Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget

Feb 26, 2026
pulisher
Feb 26, 2026

Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget

Feb 26, 2026
pulisher
Feb 26, 2026

FATE THERAPEUTICS INC SEC 10-K Report - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics reports lower Q4 collaboration revenue - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings Summary: Fate Therapeutics Q4 - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World

Feb 25, 2026
pulisher
Feb 21, 2026

Will Fate Therapeutics Inc. outperform the market in YEARTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru

Feb 21, 2026
pulisher
Feb 20, 2026

Is Fate Therapeutics Inc. stock risky to hold now2025 Geopolitical Influence & Advanced Technical Signal Analysis - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Is Fate Therapeutics Inc. subject to activist investor interestJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 19, 2026

MSN Money - MSN

Feb 19, 2026
pulisher
Feb 18, 2026

Can Fate Therapeutics Inc. lead its sector in growthJuly 2025 Technicals & Fast Entry and Exit Trade Plans - mfd.ru

Feb 18, 2026
pulisher
Feb 17, 2026

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GuruFocus

Feb 17, 2026
pulisher
Feb 16, 2026

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times

Feb 16, 2026
pulisher
Feb 14, 2026

What analysts say about Fate Therapeutics Inc. stock2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru

Feb 14, 2026
pulisher
Feb 13, 2026

FATE PE Ratio & Valuation, Is FATE Overvalued - Intellectia AI

Feb 13, 2026
pulisher
Feb 13, 2026

S P Trends: What analysts say about Fate Therapeutics Inc stock2025 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn

Feb 13, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World

Feb 10, 2026
pulisher
Feb 08, 2026

Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Feb 08, 2026
pulisher
Jan 31, 2026

Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Jan 31, 2026
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):